GC511B / AstraZeneca - LARVOL DELTA

This Study is an Open-lable, Phase I Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. (clinicaltrials.gov) - P1 | N=55 | Not yet recruiting | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

First-in-human • New P1 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor